Corcept Therapeutics Q2 revenue estimates, raises 2026 outlook

Overview

• U.S. biopharma firm's Q2 revenue rose 32% yr/yr, beating analyst expectations

• Net income for Q2 increased to $43.0 mln from $35.1 mln last year

• Company raised 2026 revenue guidance to $1.1–$1.2 bln

Outlook

• Corcept raises 2026 revenue guidance to $1.1–$1.2 bln

• Company expects FDA decision on relacorilant for Cushing’s syndrome by Dec 17, 2026

• Corcept anticipates results from key clinical trials by end of 2026 and 2027

Result Drivers

• LIFYORLI LAUNCH - Q2 benefited from initial sales of Lifyorli, with over 1,300 patients starting treatment since its FDA approval in March 2026

• CUSHING’S SYNDROME PRESCRIPTIONS - Record new prescriptions for Korlym and its authorized generic, attributed to increased physician recognition of hypercortisolism’s prevalence and need for treatment

• OPERATING EXPENSES - Higher operating expenses driven by Lifyorli launch and investments in Cushing’s syndrome business

Company press release: ID:nBwbxZl04a

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Corcept Therapeutics Inc is $91.50, about 2.9% below its July 28 closing price of $94.19

• The stock recently traded at 51 times the next 12-month earnings vs. a P/E of 52 three months ago

Reuters Recommended Reads

• July 29 - Biogen beats quarterly estimates as newer drugs drive growth

• July 29 - Processa buys Vidya Therapeutics, raises $200 million for drug trials

• July 28 - Incyte lifts annual revenue forecast after settlement with CMS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)